<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Combined cardiovascular disease outcomes with lisinopril versus chlorthalidone in ALLHAT</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Combined cardiovascular disease outcomes with lisinopril versus chlorthalidone in ALLHAT</h1>
<div class="graphic"><div class="figure"><div class="ttl">Combined cardiovascular disease outcomes with lisinopril versus chlorthalidone in ALLHAT</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Increased relative risk of cardiovascular outcomes with lisinopril. Graph, with natural logarithmic scale, showing the relative risk of combined cardiovascular disease outcomes in all patients (total) and prespecified subgroups given either lisinopril or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, lisinopril increased the risk of these outcomes in total and in most subgroups.</div><div class="graphic_reference">Data from the ALLHAT investigators, JAMA 2002; 288:2981.</div><div id="graphicVersion">Graphic 52700 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
